Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.

Author: LearJohn T, LewisLionel D, MorrisLinda M, NessDylan B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Sonidegib and vismodegib are the only FDA and EMA-approved small-molecule Hedgehog pathway inhibitors (HHIs) for treating advanced or refractory basal cell carcinoma (BCC). There are no head-to-head clinical trials comparing these two HHIs for efficacy and safety.
Paper Details　
Original Abstract of the Article :
Sonidegib and vismodegib are currently the only US Food and Drug Administration and European Medicines Agency-approved small-molecule Hedgehog pathway inhibitors (HHIs)for treating adults with advanced or refractory basal cell carcinoma (BCC) that is not amenable to conventional surgery or radiother...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17512433.2023.2285849

データ提供：米国国立医学図書館（NLM）

Navigating the Hedgehog Pathway for Basal Cell Carcinoma

Basal cell carcinoma (BCC), a common skin cancer, can feel like an unwelcome intruder in the vast desert of our skin. This study explores the use of Hedgehog pathway inhibitors (HHIs) for treating advanced or refractory BCC. The researchers investigate the pharmacokinetics and pharmacodynamics of two HHIs, sonidegib and vismodegib, currently approved for treating this type of cancer.

Hedgehog Pathway Inhibitors: A Potential Tool for BCC

The study found that [研究結果]. This finding suggests that [社会的な意義] and provides valuable insights into the potential of HHIs for managing advanced BCC.

Understanding the Treatment Landscape for BCC

The research offers valuable insights for patients and clinicians managing BCC. The study found that [研究結果]. It is important to consult with a healthcare provider for personalized treatment recommendations and to discuss any potential side effects or concerns.

Dr.Camel's Conclusion

This study provides a roadmap through the complex terrain of BCC treatment, highlighting the potential of HHIs as a valuable tool for managing advanced or refractory forms of this cancer. While both sonidegib and vismodegib show promise, further research is needed to determine the optimal HHI for specific patient populations and to explore the long-term effects of these therapies.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-12-09
Further Info :

Pubmed ID

37975712

DOI: Digital Object Identifier

10.1080/17512433.2023.2285849

Related Literature

Article Analysis
・Effects of sonidegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.